Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon19 and exon 21 mutations treated with gefitinib or erlotinib
- Author
- RIELY, Gregory J1 ; PAO, William1 2 ; PHAM, Duykhanh3 ; LI, Allan R4 ; RIZVI, Naiyer1 ; VENKATRAMAN, Ennapadam S5 ; ZAKOWSKI, Maureen F4 ; KRIS, Mark G1 ; LADANYI, Marc4 ; MILLER, Vincent A1
[1] Thoracic Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, United States
[2] Department of Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York, United States
[3] Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, United States
[4] Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, United States
[5] Department of Biostatistics Service, Memorial Sloan-Kettering Cancer Center, New York, New York, United States - Source
Clinical cancer research. 2006, Vol 12, Num 3, pp 839-844, 6 p ; 1 ; ref : 32 ref
- ISSN
- 1078-0432
- Scientific domain
- Medical oncology; Pharmacology drugs
- Publisher
- American Association for Cancer Research, Philadelphia, PA
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Anticancéreux Cancer du poumon Carcinome non petite cellule bronchopulmonaire Erlotinib Exon Géfitinib Génétique Homme Mutation Récepteur facteur croissance épiderme Récepteur facteur croissance Traitement Inhibiteur tyrosine kinase Appareil respiratoire pathologie Bronche pathologie Enzyme Inhibiteur enzyme Poumon pathologie Protein-tyrosine kinase Quinazoline dérivé Transferases Tumeur maligne
- Keyword (en)
- Antineoplastic agent Lung cancer non-small cell lung carcinoma Erlotinib Exon Gefitinib Genetics Human Mutation Epidermal growth factor receptor Growth factor receptor Treatment Respiratory disease Bronchus disease Enzyme Enzyme inhibitor Lung disease Protein-tyrosine kinase Quinazoline derivatives Transferases Malignant tumor
- Keyword (es)
- Anticanceroso Cáncer del pulmón Carcinoma no pequeňa célula bronchopulmonar Erlotinib Exón Gefitinib Genética Hombre Mutación Receptor factor crecimiento epidermi Receptor factor crecimiento Tratamiento Aparato respiratorio patología Bronquio patología Enzima Inhibidor enzima Pulmón patología Protein-tyrosine kinase Transferases Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B11 Pneumology / 002B11A Tumors of the respiratory system and mediastinum
- Discipline
- Pharmacological treatments Pulmonology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 17515757
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1158/1078-0432.CCR-05-1846 
https://dx.doi.org/10.1158/1078-0432.CCR-05-1846
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-05-1846\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:161:\"Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon19 and exon 21 mutations treated with gefitinib or erlotinib\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Clinical cancer research\";s:9:\"\u0000*\u0000stitle\";s:16:\"Clin. cancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"12\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"839\";s:8:\"\u0000*\u0000epage\";s:3:\"844\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"RIELY\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Gregory J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:12:\"PAO, William\";i:1;s:14:\"PHAM, Duykhanh\";i:2;s:11:\"LI, Allan R\";i:3;s:13:\"RIZVI, Naiyer\";i:4;s:24:\"VENKATRAMAN, Ennapadam S\";i:5;s:19:\"ZAKOWSKI, Maureen F\";i:6;s:12:\"KRIS, Mark G\";i:7;s:13:\"LADANYI, Marc\";i:8;s:17:\"MILLER, Vincent A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:1:\"1\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:161:\"Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon19 and exon 21 mutations treated with gefitinib or erlotinib\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-05-1846\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:161:\"Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon19 and exon 21 mutations treated with gefitinib or erlotinib\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Clinical cancer research\";s:9:\"\u0000*\u0000stitle\";s:16:\"Clin. cancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"12\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"839\";s:8:\"\u0000*\u0000epage\";s:3:\"844\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"RIELY\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Gregory J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:12:\"PAO, William\";i:1;s:14:\"PHAM, Duykhanh\";i:2;s:11:\"LI, Allan R\";i:3;s:13:\"RIZVI, Naiyer\";i:4;s:24:\"VENKATRAMAN, Ennapadam S\";i:5;s:19:\"ZAKOWSKI, Maureen F\";i:6;s:12:\"KRIS, Mark G\";i:7;s:13:\"LADANYI, Marc\";i:8;s:17:\"MILLER, Vincent A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:1:\"1\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:161:\"Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon19 and exon 21 mutations treated with gefitinib or erlotinib\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-05-1846\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-05-1846\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:161:\"Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon19 and exon 21 mutations treated with gefitinib or erlotinib\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Clinical cancer research\";s:9:\"\u0000*\u0000stitle\";s:16:\"Clin. cancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"12\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"839\";s:8:\"\u0000*\u0000epage\";s:3:\"844\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"RIELY\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Gregory J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:12:\"PAO, William\";i:1;s:14:\"PHAM, Duykhanh\";i:2;s:11:\"LI, Allan R\";i:3;s:13:\"RIZVI, Naiyer\";i:4;s:24:\"VENKATRAMAN, Ennapadam S\";i:5;s:19:\"ZAKOWSKI, Maureen F\";i:6;s:12:\"KRIS, Mark G\";i:7;s:13:\"LADANYI, Marc\";i:8;s:17:\"MILLER, Vincent A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:1:\"1\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:161:\"Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon19 and exon 21 mutations treated with gefitinib or erlotinib\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-05-1846\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:161:\"Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon19 and exon 21 mutations treated with gefitinib or erlotinib\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Clinical cancer research\";s:9:\"\u0000*\u0000stitle\";s:16:\"Clin. cancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"12\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"839\";s:8:\"\u0000*\u0000epage\";s:3:\"844\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"RIELY\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Gregory J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:12:\"PAO, William\";i:1;s:14:\"PHAM, Duykhanh\";i:2;s:11:\"LI, Allan R\";i:3;s:13:\"RIZVI, Naiyer\";i:4;s:24:\"VENKATRAMAN, Ennapadam S\";i:5;s:19:\"ZAKOWSKI, Maureen F\";i:6;s:12:\"KRIS, Mark G\";i:7;s:13:\"LADANYI, Marc\";i:8;s:17:\"MILLER, Vincent A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:1:\"1\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:161:\"Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon19 and exon 21 mutations treated with gefitinib or erlotinib\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-05-1846\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:161:\"Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon19 and exon 21 mutations treated with gefitinib or erlotinib\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Clinical cancer research\";s:9:\"\u0000*\u0000stitle\";s:16:\"Clin. cancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"12\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"839\";s:8:\"\u0000*\u0000epage\";s:3:\"844\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"RIELY\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Gregory J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:12:\"PAO, William\";i:1;s:14:\"PHAM, Duykhanh\";i:2;s:11:\"LI, Allan R\";i:3;s:13:\"RIZVI, Naiyer\";i:4;s:24:\"VENKATRAMAN, Ennapadam S\";i:5;s:19:\"ZAKOWSKI, Maureen F\";i:6;s:12:\"KRIS, Mark G\";i:7;s:13:\"LADANYI, Marc\";i:8;s:17:\"MILLER, Vincent A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:1:\"1\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:161:\"Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon19 and exon 21 mutations treated with gefitinib or erlotinib\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
